Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC

Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC

Introduction: Patients with EGFR-mutant NSCLC have a high incidence of brain metastases. The EGFR-directed tyrosine kinase inhibitor osimertinib has intracranial activity, making the role of local central nervous system (CNS)-directed therapies, such as radiation and surgery, less clear. Methods: Pa...

Full description

Bibliographic Details
Main Authors: Brandon S. Imber, MD, MA, Ryka Sehgal, MD, Rachel Saganty, MD, Anne S. Reiner, MPH, A. Turan Ilica, MD, Emily Miao, PharmD, Bob T. Li, MD, Gregory J. Riely, MD, Helena A. Yu, MD, Katherine S. Panageas, DrPH, Robert J. Young, MD, Luke R.G. Pike, MD, DPhil, Nelson S. Moss, MD
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:JTO Clinical and Research Reports
Subjects:
Brain metastasis
Local recurrence
EGFR-mutant
Osimertinib
Non–small cell lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001509

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001509

Similar Items